Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer

Jean Bao, Nicholas Borja, Madhu Rao, James Huth, A. Marilyn Leitch, Aeisha Rivers, Rachel Wooldridge, Roshni Rao

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Triple-negative breast cancer (TNBC) is an uncommon but aggressive subtype of breast cancer. Obesity has been associated with an increased risk of breast cancer and worse prognosis. Some studies suggest that obese patients are less likely to achieve pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) and experience worse overall survival. Ki-67 is a proliferation marker that correlates with tumor aggressiveness. The goal of this study was to examine the impact of weight change during NCT for TNBC on pathologic response and Ki-67 reduction. Retrospective review identified 173 TNBC patients treated between 2004 and 2011. Data were collected on patient demographics, pre- and post-NCT body mass index (BMI), Ki-67, and pCR. Data analysis was performed using the two-tailed Student's t-test, analysis of variance (ANOVA), and Fisher's exact test. Sixty-six patients met final study criteria. Forty-three patients lost weight during chemotherapy and 23 gained weight. Patients in the weight gain group were significantly younger (P = 0.0013). There was no significant difference between the two groups in terms of Ki-67 reduction (P = 0.98) or pCR (P = 0.58). When patients were separated into normal weight (BMI<25 kg/m(2) ), overweight (BMI ≥ 25 and <30 kg/m(2) ), and obese (BMI ≥ 30 kg/m(2) ), there was no significant difference in Ki-67 among those groups either before or after NCT. The degree of obesity did not have a significant impact on Ki-67 reduction. Weight change during NCT does not appear to correlate with Ki-67 change or achieving pCR in TNBC. This may reflect the nature of this subtype of breast cancer that is less responsive to the hormonal effects that adipose tissue exerts on cancer cell proliferation.

Original languageEnglish (US)
Pages (from-to)500-506
Number of pages7
JournalCancer Medicine
Volume4
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Triple Negative Breast Neoplasms
Weights and Measures
Drug Therapy
Breast Neoplasms
Body Mass Index
Obesity
Weight Gain
Adipose Tissue
Neoplasms
Analysis of Variance
Cell Proliferation
Demography
Students
Survival

Keywords

  • Ki-67
  • neoadjuvant chemotherapy
  • triple-negative breast cancer
  • weight change

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer. / Bao, Jean; Borja, Nicholas; Rao, Madhu; Huth, James; Leitch, A. Marilyn; Rivers, Aeisha; Wooldridge, Rachel; Rao, Roshni.

In: Cancer Medicine, Vol. 4, No. 4, 01.04.2015, p. 500-506.

Research output: Contribution to journalArticle

@article{6545536a0db246c9887cb4b97e26a3a2,
title = "Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer",
abstract = "Triple-negative breast cancer (TNBC) is an uncommon but aggressive subtype of breast cancer. Obesity has been associated with an increased risk of breast cancer and worse prognosis. Some studies suggest that obese patients are less likely to achieve pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) and experience worse overall survival. Ki-67 is a proliferation marker that correlates with tumor aggressiveness. The goal of this study was to examine the impact of weight change during NCT for TNBC on pathologic response and Ki-67 reduction. Retrospective review identified 173 TNBC patients treated between 2004 and 2011. Data were collected on patient demographics, pre- and post-NCT body mass index (BMI), Ki-67, and pCR. Data analysis was performed using the two-tailed Student's t-test, analysis of variance (ANOVA), and Fisher's exact test. Sixty-six patients met final study criteria. Forty-three patients lost weight during chemotherapy and 23 gained weight. Patients in the weight gain group were significantly younger (P = 0.0013). There was no significant difference between the two groups in terms of Ki-67 reduction (P = 0.98) or pCR (P = 0.58). When patients were separated into normal weight (BMI<25 kg/m(2) ), overweight (BMI ≥ 25 and <30 kg/m(2) ), and obese (BMI ≥ 30 kg/m(2) ), there was no significant difference in Ki-67 among those groups either before or after NCT. The degree of obesity did not have a significant impact on Ki-67 reduction. Weight change during NCT does not appear to correlate with Ki-67 change or achieving pCR in TNBC. This may reflect the nature of this subtype of breast cancer that is less responsive to the hormonal effects that adipose tissue exerts on cancer cell proliferation.",
keywords = "Ki-67, neoadjuvant chemotherapy, triple-negative breast cancer, weight change",
author = "Jean Bao and Nicholas Borja and Madhu Rao and James Huth and Leitch, {A. Marilyn} and Aeisha Rivers and Rachel Wooldridge and Roshni Rao",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/cam4.388",
language = "English (US)",
volume = "4",
pages = "500--506",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer

AU - Bao, Jean

AU - Borja, Nicholas

AU - Rao, Madhu

AU - Huth, James

AU - Leitch, A. Marilyn

AU - Rivers, Aeisha

AU - Wooldridge, Rachel

AU - Rao, Roshni

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Triple-negative breast cancer (TNBC) is an uncommon but aggressive subtype of breast cancer. Obesity has been associated with an increased risk of breast cancer and worse prognosis. Some studies suggest that obese patients are less likely to achieve pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) and experience worse overall survival. Ki-67 is a proliferation marker that correlates with tumor aggressiveness. The goal of this study was to examine the impact of weight change during NCT for TNBC on pathologic response and Ki-67 reduction. Retrospective review identified 173 TNBC patients treated between 2004 and 2011. Data were collected on patient demographics, pre- and post-NCT body mass index (BMI), Ki-67, and pCR. Data analysis was performed using the two-tailed Student's t-test, analysis of variance (ANOVA), and Fisher's exact test. Sixty-six patients met final study criteria. Forty-three patients lost weight during chemotherapy and 23 gained weight. Patients in the weight gain group were significantly younger (P = 0.0013). There was no significant difference between the two groups in terms of Ki-67 reduction (P = 0.98) or pCR (P = 0.58). When patients were separated into normal weight (BMI<25 kg/m(2) ), overweight (BMI ≥ 25 and <30 kg/m(2) ), and obese (BMI ≥ 30 kg/m(2) ), there was no significant difference in Ki-67 among those groups either before or after NCT. The degree of obesity did not have a significant impact on Ki-67 reduction. Weight change during NCT does not appear to correlate with Ki-67 change or achieving pCR in TNBC. This may reflect the nature of this subtype of breast cancer that is less responsive to the hormonal effects that adipose tissue exerts on cancer cell proliferation.

AB - Triple-negative breast cancer (TNBC) is an uncommon but aggressive subtype of breast cancer. Obesity has been associated with an increased risk of breast cancer and worse prognosis. Some studies suggest that obese patients are less likely to achieve pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) and experience worse overall survival. Ki-67 is a proliferation marker that correlates with tumor aggressiveness. The goal of this study was to examine the impact of weight change during NCT for TNBC on pathologic response and Ki-67 reduction. Retrospective review identified 173 TNBC patients treated between 2004 and 2011. Data were collected on patient demographics, pre- and post-NCT body mass index (BMI), Ki-67, and pCR. Data analysis was performed using the two-tailed Student's t-test, analysis of variance (ANOVA), and Fisher's exact test. Sixty-six patients met final study criteria. Forty-three patients lost weight during chemotherapy and 23 gained weight. Patients in the weight gain group were significantly younger (P = 0.0013). There was no significant difference between the two groups in terms of Ki-67 reduction (P = 0.98) or pCR (P = 0.58). When patients were separated into normal weight (BMI<25 kg/m(2) ), overweight (BMI ≥ 25 and <30 kg/m(2) ), and obese (BMI ≥ 30 kg/m(2) ), there was no significant difference in Ki-67 among those groups either before or after NCT. The degree of obesity did not have a significant impact on Ki-67 reduction. Weight change during NCT does not appear to correlate with Ki-67 change or achieving pCR in TNBC. This may reflect the nature of this subtype of breast cancer that is less responsive to the hormonal effects that adipose tissue exerts on cancer cell proliferation.

KW - Ki-67

KW - neoadjuvant chemotherapy

KW - triple-negative breast cancer

KW - weight change

UR - http://www.scopus.com/inward/record.url?scp=84984863741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984863741&partnerID=8YFLogxK

U2 - 10.1002/cam4.388

DO - 10.1002/cam4.388

M3 - Article

VL - 4

SP - 500

EP - 506

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 4

ER -